These results have led us to ask the question of whether SF3B1, as a critical component of the spliceosome complex and known to be frequently mutated in CLL, is a marker in the variable response and unexplained resistance to the MDM2 inhibitors in a small subset of patient samples. This evidence concerns the gene MDM2 and B-cell chronic lymphocytic leukemia.